After grabbing 1.82 million shares, the institutional investor is now in possession of 1.82 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 9.99% having worth around $0.47 million. Moreover, Yorkville Advisors Global LP increased its share by 0.6 million to have a control over 0.6 million shares. And Citadel Securities LLC raised its holdings to 31426.0 shares by acquiring 39865.0 shares or 0.22% of the stake.
Kiromic BioPharma Inc. (KRBP) concluded trading on 01/12/23 at a closing price of $0.22, with 0.35 million shares of worth about $76781.54 changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -46.31% during that period and on Thursday the price saw a gain of about 4.60%. Currently the company’s common shares owned by public are about 15.84M shares, out of which, 15.52M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 4 times over the past 12 months. They bought 755,538 shares in 4 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Fidelity Nasdaq Composite Index F, Fidelity Extended Market Index Fu, and USAA Extended Market Index Fund are the top 3 mutual funds which are holding stakes in Kiromic BioPharma Inc. Fidelity Nasdaq Composite Index F is currently holding 36662.0 shares of worth totaling $9459.0. The company recently came buying 0.0 shares which brought its stake up to 0.20% of the company’s outstanding shares. USAA Extended Market Index Fund, after selling 0.0 shares, have now control over 0.00% of the stake in the company. It holds 1899.0 shares of worth $0.0.
However, the stock later moved at a day high price of 0.2350, or with a gain of 4.60%. Stock saw a price change of 16.05% in past 5 days and over the past one month there was a price change of -11.80%. Year-to-date (YTD), KRBP shares are showing a performance of 22.03% which decreased to -85.87% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.15 but also hit the highest price of $1.62 during that period. The average intraday trading volume for Kiromic BioPharma Inc. shares is 95.43K. The stock is currently trading 12.71% above its 20-day simple moving average (SMA20), while that difference is down -8.15% for SMA50 and it goes to -44.22% lower than SMA200.
Sabby Management LLC acquired 1.82 million shares of Kiromic BioPharma Inc. having value of about $0.47 million. Kiromic BioPharma Inc. (NASDAQ: KRBP) currently have 15.84M outstanding shares and institutions hold larger chunk of about 1.70% of that. Holding of mutual funds in the company is about 10.82% while other institutional holders and individual stake holders have control over 14.76% and 0.22% of the stake respectively.
The stock has a current market capitalization of $4.29M. It has posted earnings per share of -$2.46 in the same period. It has Quick Ratio of 0.20 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KRBP, volatility over the week remained 15.38% while standing at 20.01% over the month.
Analysts are in expectations that Kiromic BioPharma Inc. (KRBP) stock would likely to be making an EPS of -$0.56 in the current quarter, while forecast for next quarter EPS is -$0.57 and it is -$2.37 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.56 which is -$0.56 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.4 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 16.70% while it is estimated to increase by 33.50% in next year.
Analysts at 0 brokerage firms have issued recommendations for the Kiromic BioPharma Inc. (KRBP)’s stock out of those 0 Wall Street analysts, 0 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.